Koo Foundation Sun Yat-Sen Cancer Center
Taipei, Taiwan
15 recruiting
Showing 1–15 of 15 trials
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer
Hoffmann-La Roche450 enrolled210 locationsNCT06790693
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled204 locationsNCT06801834
Recruiting
Phase 3
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Metastatic Breast Cancer
Sermonix Pharmaceuticals Inc.500 enrolled222 locationsNCT05696626
Recruiting
Phase 2Phase 3
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Solid Cancer
Daiichi Sankyo860 enrolled120 locationsNCT06161025
Recruiting
Phase 3
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Daiichi Sankyo686 enrolled100 locationsNCT06899126
Recruiting
Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Metastatic Non Small Cell Lung Cancer
Daiichi Sankyo740 enrolled243 locationsNCT05215340
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Pfizer400 enrolled153 locationsNCT07062965
Recruiting
Phase 3
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Peripheral T Cell Lymphoma
Dizal Pharmaceuticals218 enrolled50 locationsNCT07234162
Recruiting
Phase 1
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Diffuse Large B Cell LymphomaHigh-grade B-cell Lymphoma
ADC Therapeutics S.A.56 enrolled14 locationsNCT05660395
Recruiting
The Registry Study of Genetic Alterations of Melanoma in Taiwan
Primary Melanoma of the Extremity
National Health Research Institutes, Taiwan250 enrolled16 locationsNCT06952400
Recruiting
Not Applicable
Ga-68-FAPI-46 PET for CRC Recurrence Detection in Elevated CEA
Colorectal Cancer Recurrent
Koo Foundation Sun Yat-Sen Cancer Center30 enrolled1 locationNCT06769828
Recruiting
Phase 1Phase 2
NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma
Malignant NeoplasmMalignant Neoplasm of Brain
Novelwise Pharmaceutical Corporation79 enrolled5 locationsNCT06012695
Recruiting
Phase 2
Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma
Indolent B-Cell Non-Hodgkin Lymphoma
Koo Foundation Sun Yat-Sen Cancer Center15 enrolled1 locationNCT06461182